LTB4 increases nasal neutrophil activity and conditions neutrophils to exert antiviral effects.

Authors:
Widegren H; Andersson M; Borgeat P; Flamand L; Johnston S and 1 more

Journal:
Respir Med

Publication Year: 2011

DOI:
10.1016/j.rmed.2010.12.021

PMCID:
PMC7127613

PMID:
21251805

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Respir Med

Abbreviation: Respir Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Analysis of inflammatory protein profiles in the circulation of COVID-19 patients identifies patien…
Keur N; Saridaki M; Ricaño-Ponce I and 3 more (2023) - Transparency Score: 4/6
Lung parenchymal abnormalities and outcomes in hospitalized patients with COVID 19 pneumonia: A pos…
Datta B; Prakash AK; Yaddanapudi K and 7 more (2023) - Transparency Score: 3/6
Lung ultrasound as a tool for monitoring the interstitial changes in recently hospitalised patients…
Loke TK; Earl N; Begbey ACH and 7 more (2023) - Transparency Score: 3/6
Multiple manifestations of uncontrolled asthma increase the risk of severe COVID-19.
Selberg S; Karlsson Sundbaum J; Konradsen JR and 4 more (2023) - Transparency Score: 3/6
Pneumothorax in hospitalized COVID-19 patients with severe respiratory failure: Risk factors and ou…
Ragnoli B; Cena T; Radaeli A and 5 more (2023) - Transparency Score: 1/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest statement Pierre Borgeat, Louis Flamand, Lennart Greiff and Sebastian Johnston recieved temporary grants from LTB4 Sweden AB, which partly financed the study. LTB4 Sweden AB took part in deciding the study design but had no role in data collection and analysis, decision to publish, or preparation of the manuscript. Otherwise, the authors report no competing interest."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025